ABGSC acted as sole global coordinator and sole bookrunner in the SEK 100m directed share issue in Oncopeptides

On 13 October 2026, Oncopeptides AB (publ) (“Oncopeptides” or the “Company”), a biotech company focused on difficult-to-treat cancers, announced the successful completion of a directed share issue, raising gross proceeds of SEK 100 million through the issue of 50,000,000 new ordinary shares at a subscription price of SEK 2.00 per share.

The transaction attracted Swedish and international institutional investors. The net proceeds will enable the Company to advance its glioblastoma programme by carrying out the required CMC activities, completing preparations for clinical study start, and financing the next phase of clinical development. The financing will support continued development towards an important clinical milestone, following the promising Window-of-Opportunity data announced on 9 October 2026.

ABG Sundal Collier acted as Sole Global Coordinator and Sole Bookrunner in connection with the equity raise. We congratulate Oncopeptides on the successful financing and would like to extend our gratitude for the vote of confidence.